ModifiedBlue Cross Blue Shield - LouisianaPolicy AHS - G2105

Immunopharmacologic Monitoring of Therapeutic Serum Antibodies

This policy governs coverage of serum drug level and anti-drug antibody testing for therapeutic biologic agents (primarily anti-TNF and related biologics), specifying when testing meets coverage criteria (notably for inflammatory bowel disease) and when it does not. It applies to Blue Cross and Blue Shield of Louisiana members.

Policy Summary

PayerBlue Cross Blue Shield - Louisiana

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy AHS - G2105

Change TypeMaterial revisions and non-material updates (coverage clarificationscode additionsliterature updates)

Effective DateMay 15, 2022

Next Review Date

Key ActionObtain prior authorization and document active IBD or loss of response; testing allowed once every two weeks for individuals with IBD receiving anti-TNF, vedolizumab, or ustekinumab.

SourceLink

POLICY UPDATE CHANGES

Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references; literature review did not necessitate any modifications to coverage criteria.

Literature review necessitated combining CC1 and CC2 and editing for clarity on frequency of allowed TDM; CC1 now specifies testing once every two weeks for certain therapies.

Added CPT codes 0514U and 0515U to the procedure code list.

CC3 edited to clarify that TDM outside of IBD is not covered; language changed to 'For individuals without inflammatory bowel disease ... DOES NOT MEET COVERAGE CRITERIA.'

Every 2 wksIBD frequency

10 drugs

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

inv-01: Coverage for IBD monitoring

Covered when ALL of the following are met

IBD monitoring coverage: Individual has inflammatory bowel disease (IBD) AND testing is drug and/or antibody concentration testing for anti-TNF therapies, vedolizumab, or ustekinumab performed once every two weekstesting frequency: once every two weeks

Meets coverage criteria as specified in policy

inv-02: Not covered: non-IBD indications and other situations

Not covered when ANY of the following apply

Non-IBD or unspecified situations: Individual has a condition other than IBD (e.g., spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis) AND request is for drug and/or antibody concentration testing for anti-TNF therapiesapplies to listed non-IBD conditions

Does not meet coverage criteria

Other situations for listed drugs: Measurement of serum drug levels and/or antibodies for the following drugs in situations not otherwise addressed: adalimumab, certolizumab, etanercept, golimumab, infliximab, infliximab-dyyb, infliximab-abda, rituximab, ustekinumab, vedolizumabdrug list

Does not meet coverage criteria

inv-03: Indications (reactive and selected proactive for anti-TNFs)

Covered when ANY of the following clinical scenarios prompt testing (reactive TDM emphasized by guideline groups):

Indications for TDM: 1) Documented active inflammatory bowel disease or clinical evidence of flare; 2) Confirmed primary non-response to biologic therapy; 3) Confirmed secondary loss of response to biologic therapy; 4) At end of induction or at least once during maintenance for anti-TNF agents (consensus supports proactive post-induction and at least once during maintenance).

Reactive TDM has stronger guideline support; proactive TDM supported by consensus for anti-TNFs.

inv-04: Actionable interpretation guidance

Interpretation-based actions tied to measured drug and antibody levels:

Interpretation and actions: - Detectable adequate trough drug concentration without antibodies: continue current therapy; - Low or undetectable drug concentration with high‑titer anti‑drug antibodies: consider change of therapy (switch within or out of class) rather than dose escalation; - Low or undetectable drug concentration without antibodies: consider dose escalation or optimization; - Drug concentrations above high thresholds (eg, infliximab or adalimumab >10–15 μg/mL) argue against abandoning the current anti‑TNF agent; - Specific trough targets vary by agent and timepoint (see agent-specific thresholds).

Assay-specific antibody cutoffs noted for infliximab (eg ANSER 10 U/mL, RIDASCREEN 200 ng/mL, InformTx/Lisa Tracker 200 ng/mL).

inv-05: TDM coverage criteria

Covered when guidance-based conditions are met:

Reactive TDM should be performed in patients with confirmed primary non-response or confirmed secondary loss of response to anti‑TNF therapy, vedolizumab, or ustekinumab prior to switching or changing therapy.

Supported by consensus statements (high agreement).

Proactive TDM for anti-TNF: Proactive TDM should be performed post‑induction and at least once during maintenance for patients treated with anti‑TNF therapy; proactive monitoring is particularly important in more severely active patients or those with higher drug clearance.

Consensus support for proactive post‑induction and maintenance monitoring for anti‑TNFs.

Therapeutic thresholds: For secondary loss of response to infliximab or adalimumab, consider achieving a trough concentration of at least 10–15 μg/mL prior to treatment discontinuation or class abandonment; low‑titer antibodies (eg, <10 U/mL by homogeneous mobility shift assay for infliximab) may be managed with optimization rather than switching.10-15 μg/mL; <10 U/mL for low‑titer antibodies

Drug and/or antibody concentration testing for indications other than inflammatory bowel disease (IBD) does not meet coverage criteria. The policy specifies that testing performed for individuals with conditions such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis requesting drug and/or antibody concentration testing for anti‑TNF therapies will be considered not covered and may be denied.

The National Institute for Health and Care Excellence (NICE) concluded that enzyme‑linked immunosorbent assay (ELISA) kits for therapeutic monitoring of TNF‑alpha inhibitors in Crohn’s disease “show promise” but that there is insufficient evidence to recommend their routine adoption. NICE further recommends use of ELISA tests as part of research or data collection and notes that more evidence is needed to determine clinical effectiveness, including in rheumatoid arthritis.

To clarify the policy intent, the exclusion for non‑IBD indications explicitly applies to individuals without inflammatory bowel disease, including but not limited to spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis. The policy revision rewords prior language to make clear that drug and/or antibody concentration testing for anti‑TNF therapies in these non‑IBD populations does not meet coverage criteria.

Measurement of serum drug levels and/or anti‑drug antibodies for the listed biologic agents in clinical situations not described as covered by this policy is considered not medically necessary / does not meet coverage criteria. The policy lists specific agents for which testing outside covered scenarios will be denied.

Routine proactive therapeutic drug monitoring (TDM) for all unselected patients in remission is not broadly supported by current guidance. The AGA and ACG emphasize reactive TDM for active disease or loss of response and do not recommend routine proactive monitoring for all patients in remission; NICE similarly found insufficient evidence to support routine adoption of ELISA‑based monitoring outside research settings. The policy therefore prioritizes reactive TDM and selective proactive monitoring (particularly for anti‑TNFs) rather than universal, routine proactive testing.

Specifically for anti‑TNF therapies, the policy clarifies that drug and/or antibody concentration testing for individuals without inflammatory bowel disease (for example, those with spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, or psoriasis) does not meet coverage criteria and testing requests in these non‑IBD indications may be denied.

Coding and Thresholds

Proprietary assay products referencedmixed

not provided

Document lists proprietary assays (OptimAbs, Prometheus ANSER, LabCorp DoseASSURE) but does not provide CPT/HCPCS codes in this part.

Procedure codes referencedmixed

80145	Adalimumab
80230	Infliximab
80280	Vedolizumab
80299	Quantitation of therapeutic drug, not elsewhere specified
82397	Chemiluminescent assay
0514U	Immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum; Proprietary test: Procise ADL™; results reported as µg/mL
0515U	Immunoassay for quantitative determination of infliximab (IFX) levels in venous serum; Proprietary test: Procise IFXT™; results reported as µg/mL

inv-14: Infliximab trough — ≥2 μg/mL associated with higher probability of remission (study thresholds referenced)

Infliximab trough associated with remissionTrough ≥2 μg/mL is associated with a greater probability of clinical remission and mucosal healing during maintenance therapy (systematic review/meta-analysis).

Study LFA findingA lateral flow assay study reported a trough concentration ≧2.1 μg/mL was associated with mucosal healing in UC patients.

Meta-analysis mean troughsMaintenance patients in remission had mean IFX trough ~3.1 μg/mL versus 0.9 μg/mL in those not in remission.

inv-15: Adalimumab / Infliximab targets mentioned — study and consensus trough targets referenced

Proactive IFX targets (study)Proactive regimen targeted IFX troughs of 3–7 μg/mL for Crohn's disease and 5–10 μg/mL for ulcerative colitis.

Provider Actions and Requirements

Prior Authorization

Clinical indication needed

For individuals with inflammatory bowel disease (IBD), testing must have a documented clinical indication: active disease, loss of response, end-of-induction assessment, or other clinician rationale tied to IBD management. Requests for drug and/or antibody concentration testing for conditions other than IBD (for example, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, or other non-IBD indications) do not meet coverage criteria and may be denied.

Testing allowed once every two weeks for individuals with IBD (biweekly).
Testing for non-IBD indications is not covered.

Documentation Required

Clinical documentation for TDM

Document the clinical status and the specific reason for testing in the medical record at the time of the request. Relevant documentation should include: disease type (Crohn’s disease or ulcerative colitis), current clinical activity (e.g., symptoms, objective markers such as CRP or fecal calprotectin), prior response to biologic therapy, timing relative to induction or maintenance dosing, recent medication changes or drug holidays, and the intended management decision to be informed by the results.

Background and Scope

Anti‑drug antibodies can neutralize biologic agents or increase drug clearance, reducing efficacy and potentially contributing to loss of response or adverse events. Therapeutic drug monitoring (TDM) measures serum drug concentrations and anti‑drug antibodies to help distinguish pharmacokinetic failure (low drug level ± antibodies) from pharmacodynamic failure (adequate drug level without antibodies), which can inform decisions such as dose optimization, addition of an immunomodulator, or switching therapies.

Definitions

inv-33: TDM — Therapeutic drug monitoring definition

Definition of TDMTherapeutic drug monitoring (TDM): measurement of serum drug levels and anti-drug antibodies to guide therapy.

PurposeUsed to inform dose adjustments, optimization, or switching of biologic therapies based on drug concentrations and immunogenicity.

Trough timingTrough concentrations should be drawn near the end of the dosing interval to assess the lowest drug level.

inv-34: ADAbs / ATI / ATA — Anti-drug antibodies definitions (examples)

ADAbs definitionAnti-drug antibodies (ADAbs): antibodies generated against biologic agents (examples include antibodies-to-infliximab [ATI] and antibodies-to-adalimumab [ATA]).

Assay examplesAssay types referenced include the homogeneous mobility shift assay (HMSA) and ELISA among others; specific antibody assay cutoffs are assay-dependent.

Revision History

2026-02-01reviewLatest

Background, guidelines, recommendations, and references were updated after literature review; no modifications to coverage criteria were required.

2025-01-01revision

Coverage criteria revised: CC1 and CC2 were combined and edited; CC1 clarified to allow drug and/or antibody concentration testing once every two weeks for individuals with IBD receiving anti-TNF, vedolizumab, or ustekinumab therapies.

2024-10-01

Policy Summary

PayerBlue Cross Blue Shield - Louisiana

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy AHS - G2105

Change TypeMaterial revisions and non-material updates (coverage clarificationscode additionsliterature updates)

Effective DateMay 15, 2022

Next Review Date

Key ActionObtain prior authorization and document active IBD or loss of response; testing allowed once every two weeks for individuals with IBD receiving anti-TNF, vedolizumab, or ustekinumab.

SourceLink

On This Page

inv-16: Drug trough concentration thresholds — post-induction and maintenance targets and related guidance

Infliximab thresholdsPost-induction minimal trough >3 μg/mL; maintenance minimal trough >3 μg/mL; concentrations >7 μg/mL associated with increased likelihood of mucosal healing; generally do not abandon IFX for active disease unless concentrations >10 μg/mL.

Adalimumab thresholdsWeek 4 minimum ≥5 μg/mL; maintenance trough >5 μg/mL; concentrations >7 μg/mL associated with mucosal healing; generally do not abandon unless concentrations >10 μg/mL.

Other agents' thresholdsCertolizumab pegol week 6 >32 μg/mL (maintenance 15 μg/mL); Golimumab week 6 ≥2.5 μg/mL (maintenance >1 μg/mL).

inv-17: ACG minimal therapeutic troughs (Crohn's disease guidance) — infliximab, adalimumab, certolizumab thresholds

ACG minimal therapeutic troughs (Crohn's guidance)Infliximab >5 μg/mL; Adalimumab >7.5 μg/mL; Certolizumab pegol >20 μg/mL.

ACG note on immunogenicity riskPatients with history of anti-TNF antibodies are at increased risk of immunogenicity to subsequent same-class agents; consider combination therapy with immunomodulators.

ACG recommendation contextACG recommends considering TDM when active Crohn's disease is documented to guide management decisions.

inv-18: Suggested trough concentration threshold prior to discontinuation — 10-15 μg/mL

Threshold before discontinuationExpert consensus: when performing reactive TDM for secondary loss of response, do not consider treatment discontinuation for infliximab or adalimumab until a drug concentration of at least 10–15 μg/mL is achieved.

RationaleHigh consensus agreement supports retaining therapy until these higher troughs are reached to avoid premature switching.

ApplicabilityApplies to secondary loss of response situations for anti-TNF agents per consensus statements.

Note

Therapy decision support

Therapeutic drug monitoring (TDM) results should be used to inform specific management decisions. Examples include dose optimization (escalation or interval shortening) when low drug levels without high-titer antibodies are present, and switching therapy when high-titer anti-drug antibodies are detected. Reactive TDM is recommended for adults with active IBD or documented loss of response to guide whether to optimize the current agent or select an alternate therapy.

Low trough levels without antibodies — consider dose intensification or optimization of the same agent.
Low/undetectable drug with high‑titer antibodies — consider switch to another agent (within-class or out-of-class).
Therapeutic/adequate trough levels with active disease — consider switching drug class.
Follow guideline-recommended trough targets when available (e.g., ACG/AGA targets).

Step Therapy

Add immunomodulator when switching within class

When switching within the anti‑TNF drug class because of secondary loss of response due to immunogenicity (development of anti‑drug antibodies), an immunomodulator (e.g., thiopurine or methotrexate) should be added to the subsequent anti‑TNF therapy to reduce the risk of immunogenicity and improve clinical outcomes. Document the rationale for adding the immunomodulator and monitor per standard clinical practice.

Consider combination therapy particularly when prior antibodies were detected or when patient has history of immunogenicity.
Document planned immunomodulator agent and monitoring plan.

inv-35: Proactive TDM — Definition of proactive TDM

Proactive TDM definedProactive TDM: scheduled monitoring of serum drug levels and anti-drug antibodies during induction and/or maintenance to maintain therapeutic concentrations and prevent loss of response (eg, post-induction and at least once during maintenance for anti-TNFs).

Support and scopeConsensus panels support proactive post-induction monitoring for anti-TNFs (vote agreement ≈90%) and selective proactive use in higher-risk patients.

Study evidenceRandomized and observational studies have demonstrated improved sustained disease control and higher mucosal healing rates with proactive strategies in some cohorts.

inv-36: Reactive TDM — Definition of reactive TDM

Reactive TDM definedReactive TDM: testing performed in response to documented primary non-response or secondary loss of response to guide treatment changes prior to switching or dose changes.

Guideline emphasisConsensus and guideline statements emphasize reactive TDM as the primary supported indication for testing across anti-TNF, vedolizumab, and ustekinumab when non-response is documented.

Clinical useReactive TDM informs whether to escalate dose, add immunomodulator, or switch therapy based on combined drug and antibody results.

inv-38: Anti-drug antibodies (general relevance) — Relevance when trough concentrations are undetectable

Relevance of ADAbs when troughs undetectableAnti-drug antibodies are more clinically relevant when trough drug concentrations are undetectable; high-titer antibodies in this setting often prompt a change of therapy.

Management implicationIn the absence of detectable drug, high-titer anti-infliximab antibodies require change of therapy; low-level antibodies may be overcome by optimization.

Assay cutoffs for high-titer ATIFor the ANSER assay a high-titer ATI at trough is defined as 10 U/mL; RIDASCREEN and InformTx/Lisa Tracker cutoffs cited as 200 ng/mL.